---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-072408"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-06-10T21:01:03+00:00"
generated_at: "2026-06-10T21:02:12.117246+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance's Amtagvi granted TGA approval in Australia for advanced melanoma

## Summary
- Therapeutic Goods Administration of Australia approved Amtagvi for previously treated advanced melanoma.
- Indicated for patients who received anti-PD-1 therapy and, if BRAF V600+, a BRAF/MEK inhibitor.
- Third marketing authorization for Amtagvi; Iovance is authorizing its first Australian treatment center.
- Australia has the world's highest melanoma rate, with ~17,000 new cases annually.
- Approval based on Phase 2 C-144-01 trial results showing objective response rate and duration of response.

## SEC filing metadata
- accession: 0001104659-26-072408
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-06-10T21:01:03+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/0001104659-26-072408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-072408
- JSON: https://secwatch.observer/filing/0001104659-26-072408.json
- Plain text: https://secwatch.observer/filing/0001104659-26-072408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.